Back to results
US 7,745,611 B2Granted
siRNA targeting KRAS
AssigneeDharmacon, Inc.
InventorsAnastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Stephen Scaringe, Steven Read
Life of this patent
Estimating the term…
Abstract
Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs directed to silencing KRAS, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.
Claims20
An siRNA molecule, wherein said siRNA molecule consists of:
- (a) a duplex region;
- and (b) either no overhangs regions or at least one overhang region, wherein each overhang region comprises six or fewer nucleotides, wherein the duplex region consists of a sense region and an antisense region, wherein said sense region and said antisense region together form said duplex region and said duplex region is 19-30 base pairs in length and said antisense region comprises a sequence that is the complement of SEQ ID NO:
- 454.
A chemically synthesized double-stranded siRNA molecule, wherein:
- (a) each strand of said siRNA molecule is between 19 and 30 nucleotides in length;
- and
- (b) one strand of said siRNA molecule comprises a sequence that is the complement of SEQ ID NO:
- 454.
1 more element
An siRNA molecule consisting of:
- (a) a duplex region;
- and
- (b) either no overhang regions or at least one overhang region, wherein each overhang region comprises six or fewer nucleotides,
- wherein the duplex region is nineteen base pairs in length and consists of a sense region that has a sequence that is the same as SEQ ID NO:
- 454 and an antisense region that has a sequence that is the complement of SEQ ID NO:
- 454.
3 more elements
Dependencies are inferred from the claim text.